The therapeutic efficacy of anti-CTLA-4 immunotherapy against intracranial gliomas requires a distal B-cell and antibody response initiated inside the tumor-draining deep cervical lymph nodes.
Trending
- Paxton’s Campaign Says He Will Debate Talarico In Texas U.S. Senate Race
- Mike’s Blog Round-Up
- Dem Candidate Turns MAGA Troll Into A Learning Moment
- Pool Report: Ts Brother Arrested For SICK Behavior Towards Children At Hotel
- Trump Biographer Describes Sitting Face-To-Face With Trump During Delirious Meltdowns
- Ohio residents sue Taco Bell, say they got cyclospora after eating at restaurants
- Sweeteners may slow down growth of gut bacteria
- Does the ‘pink salt trick’ help you lose weight?
